健脾清化散瘀饮对脾虚湿热血瘀型隆起糜烂性胃炎患者P53及PCNA的影响

林国清; 王清泉; 柯晓; 高尤亮; 林建龙; 赵培琳; 付肖岩; 王文荣; 胡光宏

doi:10.3969/j.issn.1671-038X.2016.11.02

健脾清化散瘀饮对脾虚湿热血瘀型隆起糜烂性胃炎患者P53及PCNA的影响

- 1. 福建中医药大学附属人民医院, 福建福州 350004;
- 2. 福建安溪县医院, 福建泉州 362400;
- 3. 福建中医药大学附属第二人民医院, 福建福州 350003;
- 4. 福建中医药大学, 福建福州 350122
基金项目:
福建省自然科学基金项目(No:2015J01478)

福建省卫生厅中医药科研课题(No:WZPW201302)

详细信息

通讯作者: 柯晓,E-mail:drkxkx@163.com

中图分类号: R573.3

收稿日期: 2016-05-10

Effects of Jianpi Qinghua Sanyu Yin on gastric mutant P53 and PCNA in raised erosive gastritis patients

- 1. People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou 350004, China;
- 2. Anxi Hospital of Fujian Province, Quanzhou 362400, China;
- 3. The;
- 2 nd People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou 350003, China;

More Information

Corresponding author: KE Xiao, E-mail: drkxkx@163.com

Received Date: 10 May 2016

摘要

摘要: [目的]健脾清化散瘀饮治疗脾虚湿热血瘀型隆起糜烂性胃炎(Raised erosive gastritis,REG)一个疗程后,比较治疗前后的临床疗效变化,并通过比较正常对照组和REG患者治疗前后胃黏膜组织突变型P53蛋白(P53)及细胞增殖核抗原蛋白(PCNA)的表达变化,探讨健脾清化散瘀饮治疗REG可能的作用机制。[方法]选取REG属脾虚湿热血瘀证患者36例,予以中药健脾清化散瘀饮口服治疗,3个月为一疗程。36例REG患者(以下属全分析集)中,3例临床相关资料不完整予剔除,另失访脱落1例,共32例患者(以下属符合方案集)进行统计分析,并设正常对照组20例。观察临床疗效,检测健脾清化散瘀饮治疗前后胃黏膜P53及PCNA表达的变化,进行治疗前后的自身对照,并测定20例正常对照组胃黏膜组织中P53及PCNA的表达水平同REG组治疗前后进行空白对照。[结果](1)中医证候疗效(根据症候积分评定):①符合方案集:总有效率为93.75%。②全分析集:总有效率为83.33%。(2)胃镜疗效:①符合方案集:总有效率为78.125%。②全分析集:总有效率为69.44%。(3)病理疗效:①符合方案集:总有效率为84.375%。②全分析集:总有效率为75.00%。(4)治疗前REG患者胃黏膜P53呈强阳性表达,明显髙于正常对照组(P<0.05),经健脾清化散瘀饮治疗后其表达较治疗前明显下降(P>0.05),与正常对照组比较差别无统计学意义(P>0.05)。(5)治疗前REG患者胃黏膜中PCNA的表达呈强阳性表达,表达强度明显高于正常对照组(P<0.05),治疗后其表达强度明显降低,呈弱阳性表达,且接近正常对照组表达,治疗前后比较差异有统计学意义(P<0.05)。[结论]①健脾清化散瘀饮治疗REG疗效确切。②P53及PCNA的过度表达提示REG胃黏膜细胞处于一种高增殖状态,二者介导的细胞异常增殖可能与REG发病密切相关。③健脾清化散瘀饮可能是通过下调P53及PCNA的表达以抑制细胞增殖达到治疗的目的,这可能是其治疗REG的机理之一。
- 脾虚湿热血瘀证 /
- 隆起糜烂性胃炎 /
- 健脾清化散瘀饮 /
- P53 /
- PCNA
Abstract: [Objective]To explore the effects of Jianpi Qinghua Sanyu Yin in treating raised erosive gastritis(REG)and to investigate the possible mechanisms by detecting the changes of gastric mucosa mutant P53 protein(P53)and proliferating cell nuclear antigen protein(PCNA).[Methods]Thirty-six REG patients were selected and treated with Jianpi Qinghua Sanyu Yin for 3 months.Among the 36 cases,except that 3 cases' clinically relevant information was incomplete and 1 case was lost,32 cases were sent to the final statistical analysis.Another 20 healthy people were selected as the normal control group.The changes of the syndrome,and P53 and PCNA expression as well as the adverse reactions were observed.[Results]1.Efficacy of Traditional Chinese Medicine symptoms(based on symptom score):①The total effective rate was 93.75% at the per-protocol set.②At the full analysis set,the total effective rate was 83.33%.2.Endoscopy efficacy:①The total effective rate was 78.125% at the per-protocol set.②At the full analysis set,the total effective rate was 69.44%.3.Pathological efficacy:①The total effective rate was 84.375% at the per-protocol set.②At the full analysis set,the total effective rate was 75.00%.4.Compared with the normal control group,the P53 and PCNA expression of REG group were much higher(P＜0.05).They significantly decreased after treatmen(P＜0.05),but were still higher than the normal control group.There was no significant difference between two groups(P＞0.05).[Conclusion]1.The curative effect of Jianpi Qinghua Sanyu Yin for REG is obvious.2.The abnormal expression of P53 and PCNA may play an important role in promoting the occurrence and development of REG;3.Jianpi Qinghua Sanyu Yin can significantly reduce the expression level of P53 and PCNA in REG patients,which might be the mechanism of its function.
- Raised erosive gastritis /
- Jianpi Qinghua Sanyu Yin /
- P53 /
- PCNA /

HTML全文

参考文献(22)

[1]	陆敏,田耀洲,夏军权.疣状胃炎内镜表现和病理的相关性研究[J].医学临床研究,2006,23(11):l776-1778.
[2]	付唆林.隆起糜烂性胃炎的历史、现状与思考[J].国外医学·消化系统疾病分册,2005,25(3):155-156.
[3]	柯晓,黄泽辉,方文怡,等.福州地区隆起糜烂性胃炎病理分类和中医临床证候学的研究[J].中国中西医结合消化杂志,2010,18(5):306-311.
[4]	樊代明,陈强.第十届世界胃肠病学大会报道[J].中华消化杂志,1995,15(1):171.
[5]	林燕玉,柯晓,付肖岩,等.健脾清化散瘀为主治疗隆起糜烂性胃炎的疗效观察[J].中国中西医结合消化杂志,2013,21(12):621-624.
[6]	柯晓,方文怡,周凡,等.隆起糜烂性胃炎证型与幽门螺杆菌感染及p53和增殖细胞核抗原表达的相关性[J].中国中西医结合消化杂志,2010,18(2):75-77.
[7]	白歌,胡伏莲.疣状胃炎与幽门螺杆菌的关系及其治疗的研究[J].中国内镜杂志,1997,3(1):16-17,20,79.
[8]	宋莹,于建勋,王炜佳,等.疣状胃炎、胃癌组织中幽门螺杆菌感染与p53、p21蛋白表达[J].中国老年学杂志,2006,26(10):1341-1343.
[9]	ZHANG L,HOU Y H,WU K,et al.Proteomic analysis reveals molecularbiological details in varioliform gastritis without Helicobacter pylori infection[J].World J Gastroenterol,2010,16(29):3664-3673.
[10]	丁世华,刘俊,舒晴,等.抑癌基因PTEN及P16蛋白在疣状胃炎及胃癌组织中的表达及意义[J].世界华人消化杂志,2010,18(19):2047-2049.
[11]	肖晨,苏东星,潘志刚,等.抑癌基因p16在疣状胃炎和胃癌中的表达及其意义[J].中国临床新医学,2011,4(4):303-305.
[12]	柯昌庶,王伟,王一鸣,等.慢性糜烂性胃炎与胃癌的免疫组织化学比较研究——P-(21ras)、P-(53)、PCNA和CEA表达的观察[J].临床消化病杂志,1997,9(1):7-10.
[13]	葛素兰,郭永泽,王建华,等.高频电凝联合中西药物对疣状胃炎增殖细胞核抗原的影响[J].疑难病杂志,2009,8(8):485-486.
[14]	中华中医药学会脾胃病分会.慢性浅表性胃炎中医诊疗共识意见[J].中国中西医结合消化杂志,2010,3(18):207-208.
[15]	中国中西医结合学会消化系统疾病专业委员会.慢性胃炎中西医结合诊疗共识意见[J].现代消化及介入诊疗,2012,3(17):172-177.
[16]	MUMOZ M C,MENDOZA D,PALMA E.Varioliform gastritis with in situ carcinomatous transformation[J].An Fac Med Univ Repub Montev Urug,1960,45(5):72-77.
[17]	姚忆蓉,周中源,徐诗光,等.疣状胃炎82例胃镜随访观察[J].河南医科大学学报,1995,30(4):425-427.
[18]	陈淑萍.胃液CEA、β2-MG测定与疣状胃炎关系的初步研究[J].浙江医学,2006,28(4):244-245,249.
[19]	RYU M H,KANG Y K,JANG S J,et al.Prognostic significance of p53 gene mutations and protein over expression in localized gastrointestinal stromal tumours[J].Histopathology,2007,51(3):379-389.
[20]	BRITO M J,WILLIAMS G T,THOMPSON H,et al.Expression of p53 in early(T1) gastric carcinoma and precancerous adjacent mucosa[J].Gut,1994,35(12):1697-1700.
[21]	李宏,廉斌,王建,等.Topo11、P170、GST-π、PCNA及E-Cadherin在乳腺癌组织中的表达及临床意义[J].宁夏医学杂志,2013,35(1):12-16.
[22]	邹建湘,陈玉龙,王立东,等.增殖细胞核抗原在各级胃黏膜病变中的表达[J].河南医学研究,1998,7(1):32-34.